FDA Approves Controversial Alzheimer’s Drug Despite Potential Harm

June 7, 2021 by Reece Nations
FDA Approves Controversial Alzheimer’s Drug Despite Potential Harm
In this 2019 photo provided by Biogen, a researcher works on the development of the medication aducanumab in Cambridge, Mass. On Monday, June 7, 2021, the Food and Drug Administration approved aducanumab, the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn’t been shown to help slow the brain-destroying disease. (Biogen via AP)

SILVER SPRING, Md. — The Food and Drug Administration on Monday granted its approval to aducanumab, an Alzheimer’s treatment developed by Biogen for use in patients, despite mixed clinical trial results for the drug. 

Prescribed under the brand name “Aduhelm,” the treatment is given intravenously and is meant to remove protein deposits from the brains of patients in the early stages of Alzheimer’s. The proteins are known to cause loss of memory and physical control over one’s body functions.

The effects of the drug were studied in two clinical trials — only one of which deemed Aduhelm as an effective treatment. Prior to its approval, experts on the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee concluded that it was unreasonable to maintain the clinical benefit of one successful trial as the primary evidence supporting its approval.

“We are well-aware of the attention surrounding this approval,” Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said in a written statement. “We understand that Aduhelm has garnered the attention of the press, the Alzheimer’s patient community, our elected officials, and other interested stakeholders. With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review.”


Cavazzoni continued, “Further, the data included in the applicant’s submission were highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.”


In all of its evaluations, the FDA noted Aduhelm “consistently and very convincingly” led to a reduction in the level of amyloid plaques in patient’s brains on a “dose- and time-dependent” basis. Ultimately, the administration concluded the drug satisfied the standards of its “Accelerated Approval” pathway and was likely to produce clinical benefit.

Roughly 40% of trial participants experienced brain bleeding or swelling after receiving high doses of the drug, according to study results published by Biogen. Although most participants were either asymptomatic or experienced only headaches, dizziness or nausea, the effects of the drug caused 6% of high-dose recipients to withdraw from the study.

“We ultimately decided to use the Accelerated Approval pathway — a pathway intended to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need, and where there is an expectation of clinical benefit despite some residual uncertainty regarding that benefit,” Cavazzoni continued in the FDA’s statement. “In determining that the application met the requirements for Accelerated Approval, the Agency concluded that the benefits of Aduhelm for patients with Alzheimer’s disease outweighed the risks of the therapy.”

The drug will now undergo a post-market study to determine its widespread effectiveness as an Alzheimer’s treatment. If the “Phase 4 trial” fails to demonstrate its effectiveness or leads to adverse health effects in patients, the FDA could subsequently rescind its approval — although it is not required by law.


Aduhelm is the first new Alzheimer’s treatment approved by the FDA since 2003. Roughly six million Americans and 30 million people worldwide have Alzheimer’s, according to analysis by the Alzheimer’s Association. Further, the number of new cases of Alzheimer’s and other dementias is expected to double annually by 2050.

“The consequences of FDA approval are as disturbing as they are vast,” Jason Karlawish, professor of Medicine and Medical Ethics and Senior Fellow of the Center for Bioethics at the University of Pennsylvania, wrote in an op-ed for Stat News. “Around two million Americans could be prescribed aducanumab, at an estimated cost that ranges from $20,000 to $50,000 per person per year. Biogen claims the benefits of slowing declines in cognition and day-to-day function are worth this price. I think the company is wrong, and I agree with the analyses by the Institute for Clinical and Economic Review; the data to make this case are murky and, even if they were clear, the drug’s benefits are ambiguous at best and not worth this cost. Putting it on the market will stress Medicare’s resources.”

A+
a-

In The News

Health

Voting

Health

Abortion Rights Groups Look to Next Fights After 2022 Wins

CHICAGO (AP) — Emboldened by the results of November's midterms, abortion rights supporters say they are preparing for even bigger fights... Read More

CHICAGO (AP) — Emboldened by the results of November's midterms, abortion rights supporters say they are preparing for even bigger fights in state legislatures and pivotal elections to come, including 2024 races for Congress and president. Victories for abortion rights ballot measures and candidates who support abortion provided a... Read More

November 30, 2022
by Dan McCue
GOP Senators Oppose Advancing NDAA Unless Military Vaccine Mandate Canned

WASHINGTON — A group of U.S. senators led by Sens. Rand Paul, R-Ky., and Lindsey Graham, R-S.C., said they will... Read More

WASHINGTON — A group of U.S. senators led by Sens. Rand Paul, R-Ky., and Lindsey Graham, R-S.C., said they will oppose passage of this year’s defense spending authorization unless the chamber votes to repeal the current COVID-19 vaccine mandate for military personnel. In a letter to... Read More

November 30, 2022
by Dan McCue
Initiative Makes $350M Available to Increase COVID-19 Vaccinations

WASHINGTON — The Biden administration is making $350 million available to increase COVID-19 vaccinations at Health Resources and Services Administration-supported... Read More

WASHINGTON — The Biden administration is making $350 million available to increase COVID-19 vaccinations at Health Resources and Services Administration-supported health facilities. The funding will support health centers administering updated COVID-19 vaccines through mobile, drive-up, walk-up or community-based vaccination events, including working with community-based organizations and... Read More

November 30, 2022
by Dan McCue
WHO Recommends New Name for Monkeypox Disease

GENEVA — The World Health Organization has begun using the term “mpox” as the preferred synonym for monkeypox. Both names... Read More

GENEVA — The World Health Organization has begun using the term “mpox” as the preferred synonym for monkeypox. Both names will be used simultaneously for one year while “monkeypox” is phased out, the organization said. According to the WHO, when the current outbreak of monkeypox began... Read More

November 30, 2022
by Dan McCue
WHO Urges More Effective Prevention of Injuries and Violence

GENEVA —The statistics are sobering. One in 12 deaths worldwide are caused by some form of injury and/or violence, and... Read More

GENEVA —The statistics are sobering. One in 12 deaths worldwide are caused by some form of injury and/or violence, and when all those deaths are tallied, the outcome shows that traffic accidents, drownings, falls, burns and suicides are taking the lives of some 12,000 people a... Read More

November 30, 2022
by TWN Staff
New Study Challenges ‘Good’ Cholesterol’s Role in Predicting Heart Disease Risk

BETHESDA, Md. — A new study has found that high-density lipoprotein cholesterol, the so-called "good cholesterol," may not be as... Read More

BETHESDA, Md. — A new study has found that high-density lipoprotein cholesterol, the so-called "good cholesterol," may not be as effective as scientists once believed in uniformly predicting cardiovascular disease risk among adults of different racial and ethnic backgrounds.  In fact, the research, which was supported... Read More

News From The Well
scroll top